ASRT
Price:
$0.8761
Market Cap:
$83.65M
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately seve...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1997-12-03
Stock Exchange
NASDAQ
Ticker
ASRT
According to Assertio Holdings, Inc.’s latest financial reports and current stock price. The company's current ROE is -51.19%. This represents a change of 309.91% compared to the average of -12.49% of the last 4 quarters.
The mean historical ROE of Assertio Holdings, Inc. over the last ten years is -68.56%. The current -51.19% ROE has changed -25.34% with respect to the historical average. Over the past ten years (40 quarters), ASRT's ROE was at its highest in in the March 2020 quarter at 49.06%. The ROE was at its lowest in in the December 2019 quarter at -332.35%.
Average
-68.56%
Median
-29.71%
Minimum
-374.76%
Maximum
48.57%
Discovering the peaks and valleys of Assertio Holdings, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 70.92%
Maximum Annual ROE = 48.57%
Minimum Annual Increase = -3982.76%
Minimum Annual ROE = -374.76%
Year | ROE | Change |
---|---|---|
2023 | -240.53% | -595.27% |
2022 | 48.57% | -3982.76% |
2021 | -1.25% | -97.53% |
2020 | -50.70% | -86.47% |
2019 | -374.76% | -2337.23% |
2018 | 16.75% | -127.70% |
2017 | -60.47% | 70.92% |
2016 | -35.38% | 47.16% |
2015 | -24.04% | -166.49% |
2014 | 36.15% | 14.70% |
The current ROE of Assertio Holdings, Inc. (ASRT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-64.41%
5-year avg
-123.73%
10-year avg
-68.56%
Assertio Holdings, Inc.’s ROE is less than Agile Therapeutics, Inc. (104.04%), less than Amneal Pharmaceuticals, Inc. (378.68%), greater than AcelRx Pharmaceuticals, Inc. (-118.55%), less than Lifecore Biomedical, Inc. (17.23%), greater than Ironwood Pharmaceuticals, Inc. (-7.63%), less than Neurocrine Biosciences, Inc. (15.68%), greater than Deciphera Pharmaceuticals, Inc. (-52.42%), less than Esperion Therapeutics, Inc. (23.71%), greater than ANI Pharmaceuticals, Inc. (-1.60%), less than Alkermes plc (26.49%), less than Dr. Reddy's Laboratories Limited (18.58%), less than Collegium Pharmaceutical, Inc. (40.81%), greater than Pacira BioSciences, Inc. (-10.70%), greater than Intra-Cellular Therapies, Inc. (-9.93%), greater than Catalent, Inc. (-11.44%), less than Amphastar Pharmaceuticals, Inc. (22.92%), less than Alvotech (69.49%), less than Eagle Pharmaceuticals, Inc. (17.39%), greater than Evolus, Inc. (-966.29%),
Company | ROE | Market cap |
---|---|---|
104.04% | $10.43M | |
378.68% | $3.63B | |
-118.55% | $14.58M | |
17.23% | $279.89M | |
-7.63% | $737.73M | |
15.68% | $13.82B | |
-52.42% | $2.21B | |
23.71% | $453.18M | |
-1.60% | $1.14B | |
26.49% | $4.80B | |
18.58% | $13.05B | |
40.81% | $937.19M | |
-10.70% | $898.99M | |
-9.93% | $9.04B | |
-11.44% | $11.52B | |
22.92% | $1.84B | |
69.49% | $3.79B | |
17.39% | $6.74M | |
-966.29% | $687.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Assertio Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Assertio Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Assertio Holdings, Inc.'s ROE?
How is the ROE calculated for Assertio Holdings, Inc. (ASRT)?
What is the highest ROE for Assertio Holdings, Inc. (ASRT)?
What is the 3-year average ROE for Assertio Holdings, Inc. (ASRT)?
What is the 5-year average ROE for Assertio Holdings, Inc. (ASRT)?
How does the current ROE for Assertio Holdings, Inc. (ASRT) compare to its historical average?